PD-1/PD-L1 binding activates the immune checkpoint pathway and inhibits T-cell-mediated immune responses.[4] Sintilimab, a PD-1 inhibitor developed by Innovent Biologics and Eli Lilly and Company, has been used in combination with pemetrexed and platinum as the first-line therapy for patients with advanced or recurrent non-squamous NSCLC under the approval of the National Medical Products Administration of China.[5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.